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Surgical Cyst Decortication in Autosomal Dominant
Polycystic Kidney Disease
Melissa Millar, BS,1 Youssef S. Tanagho, MD, MPH,2 Mohammed Haseebuddin, MD,2
Ralph V. Clayman, MD,3 Sam B. Bhayani, MD,2 and R. Sherburne Figenshau, MD2
Abstract
Purpose: To provide a summary of the relevant literature regarding the impact of surgical cyst decortication on
hypertension, renal function, and pain management in patients with autosomal dominant polycystic kidney
disease (ADPKD).
Methods: Data collection was conducted via a Medline search using the subject headings autosomal dominant
polycystic kidney disease, surgery, decortication, and marsupialization. Additional reports were derived from
references included within these articles.
Results: Despite a trend for improved blood pressure control after cyst decortication in some studies, this
cumulative review of the literature did not provide consistent evidence supporting the role of this procedure in
blood pressure management in patients with ADPKD. Surgical cyst decortication was associated with renal
deterioration in a subset of patients with compromised baseline renal function but did not otherwise appear to
have a significant impact on renal function in the majority of studies reviewed. Improvement in chronic pain
after this procedure was ubiquitously reported across all studies examined.
Conclusions: Despite a potential role in blood pressure management in the setting of ADPKD, surgical cyst
decortication has not been definitively shown to alleviate hypertension in this clinical setting. Renal function
does not appear to improve following this surgery. Patients with compromised baseline renal function appear to
be at increased risk for further deterioration in renal function after cyst decortication, although the role of this
procedure in altering the natural trajectory of renal failure in this patient subset needs further investigation. Cyst
decortication is highly effective in the management of disease-related chronic pain for the majority of patients
with ADPKD, providing durable pain relief in this patient population.
Introduction
Autosomal dominant polycystic kidney disease(ADPKD) is the most common monogenetic disease,
affecting 300,000 to 600,000 Americans.1 It is caused by a
genetic mutation in one of the polycystin genes, PKD1 and
PKD2, more frequently PKD1 (85%–90% of cases), which is
associatedwith earlier onset and increased severity of disease.
These genes encode membrane-spanning proteins that, if
mutated, disrupt normal function of the primary cilium on
tubule epithelial cells and are associated with a number of
functions believed to regulate tubular and vascular develop-
ment in the kidneys, liver, pancreas, heart, and brain.2 Cyst
formation occurs simultaneously with recruitment of macro-
phages and fibroblasts. As kidneys progress to end-stage
disease, cysts are surrounded by fibrosis and atrophic tubules.
The disease presents in adulthood as cysts develop inmultiple
organ systems.
The pathophysiology believed to result from cyst formation
manifests as hypertension, deteriorating renal function, and
pain. Enlarging cysts compress renal parenchyma and vas-
culature to cause an ischemia-induced activation of the renin-
angiotensin-aldosterone system (RAAS), as well as pain and
trauma to nephrons. Uncontrolled hypertension is associated
with accelerated progression to end-stage renal disease
(ESRD) and ultimately death.3,4
Treatment of patients with ADPKD is a complex and in-
exact challenge to the medical community but is traditionally
directed at improving or stabilizing renal function, controlling
pain, and treating hypertension. Optimal care of these
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patients, however, continues to be the subject of numerous
studies. The Consortium for Radiologic Imaging Studies in
PKD has recently identified serum high-density lipoprotein-
cholesterol, urine sodium excretion, and 24-hour urine os-
molality as ‘‘potentially modifiable factors’’ in a search for
therapeutic targets.5 Furthermore, drug therapies targeted to
abnormal molecular mechanisms present in ADPKD are in
various stages of clinical trials (Clinical Trials ID
NCT00428948, NCT00346918, NCT01214421). Additional
morbidity associated with ADPKD includes a debatable in-
creased incidence of renal-cell carcinoma (RCC), although
evidence suggests that when it does occur, RCC exhibits un-
ique characteristics including earlier onset, multicentricity,
and frequent bilaterality.6,7 Interestingly, none of the studies
cited in this article discuss surgical cyst decortication (CD) as
part of the management of the potential increased risk of
cancer in this patient subset.
Surgical intervention is a modality for which historic indi-
cations have included pain, hypertension, deteriorating renal
function, and the presence of malignant cysts but more re-
cently has been considered primarily for patients with
ADPKD in whom conservative measures of pain manage-
ment have failed. Surgical options include renal denervation,
cyst aspiration and decortication, and nephrectomy. Surgical
intervention by CD in patients with ADPKD has a long his-
tory in the medical literature (Table 1). As early as 1911,
Rovsing8 described three cases in which cysts were punctured
with consequent pain reduction and renal functional im-
provement. Nearly 20 years later, Meltzer9 described the
outcomes of 31 cases of surgical cyst decortication as a
‘‘.more hopeful prognosis’’ than usually described with
the primary end point of the study being postoperative
duration of life, rather than pain reduction or renal functional
improvement.
Interest in CD waned after Bricker and Patton10 reported a
rapid postoperative decline in renal function in two ADPKD
patients with suboptimal preoperative renal function. Al-
though the small sample size and lack of matched controls in
this study present a challenge in drawing definitive conclu-
sions, the authors reported regarding renal function, ‘‘the
possibility is considered tenable that the procedure was det-
rimental.’’ Despite the initial impact of this report, accounts of
CD have resurfaced in the literature, beginning in the 1980s
and continuing through the past decade with assorted reports
of its efficacy inmitigating pain, decreasing hypertension, and
altering renal functional deterioration. Variations in length of
follow-up, in the primary end points evaluated, and in
methodology complicate comparison among these studies. In
this article, we explore the therapeutic value of surgical CD by
reviewing the first study published on this procedure and
relevant contemporary studies.
Methods
A Medline search identifying published reports on CD for
ADPKD was performed using Medical subject headings
autosomal dominant polycystic kidney disease and subhead-
ings etiology, pathophysiology, prevention and control, sur-
gery, and therapy. We searched within the returned results
using AND decortication or ANDmarsupialization. Selections
were made based on studies that described outcomes in pa-
tients with ADPKD for whom surgical intervention was men-
tioned as part of the disease management. An analysis of the
references in returned Medline publications provided addi-
tional resources for this article. We did not include studies of
laparoscopic CD (LCD) in patients with simple renal cysts.
Included in the review is our own report of long-termoutcomes
after the procedure.11 Case reports and retrospective series
comprised the bulk of the pertinent literature in this review.
Results
Surgical technique
A preoperative abdominal CT image or MRI is obtained to
delineate the anatomy of the kidneys and guide treatment.
Intraoperative ultrasonography may be used to detect and
guide drainage of smaller or subcapsular cysts to maximize
the number of cysts decorticated per patient. Specimens of the
cysts may be sent for pathologic examination.
Although surgical CD has been reported since the early
19th century, the laparoscopic approach in patients with
ADPKD was initially described in 1995 by Teichman and
Hulbert12 in a case report of six patients with ADPKD, all of
whom had failed to achieve pain relief by percutaneous cyst
aspiration.8–10,13,14 At the time of their study, LCD had al-
ready been used in managing simple renal cysts. At present,
LCD, in resemblance to open CD, aims at maximizing the
number of cysts treated.
Our technique reflects these goals: As many cysts as pos-
sible are decorticated (large cysts), broadly incised (medium-
size cysts), or punctured and drained (small cysts). A careful
dissection of the renal hilum is performed, and cysts in this
area are likewise treated. Hemostasis is obtained by electro-
cautery and the argon-beam coagulator. At the end of the
procedure, the kidney is reexamined with a laparoscopic ul-
trasound unit to detect any remaining cysts within a few
millimeters of the renal surface; these cysts are also entered
and drained. A record of treated cysts is created throughout
the procedure. Nephropexy is performed.
The laparoscopic approach is recently the oft-used ap-
proach for CD, given the benefits associated with minimally
invasive surgery.15,16 study by Dunn and associates17 that
examined 9 years of experience of laparoscopic vs open rad-
ical nephrectomy demonstrates a dramatic reduction in esti-
mated blood loss (172 vs 451mL), hospital stay (3.4 vs 5.2
days), and time to normal activity (3.6 vs 8.1 weeks) using a
laparoscopic approach.
Time to ambulation, mean hospital stay, and other pa-
rameters pertaining to postoperative recovery, however, will
vary, depending on both the degree of surgical invasiveness
as well as baseline patient characteristics (eg, age, comorbid-
ities).18,19
Hypertension
Currently, there is no consensus regarding the optimal
management of hypertension in ADPKD patients, although
increased use of antihypertensive agents has been associated
with decreased mortality in this patient population.20–22 To
this end, research in the Halt Progression of PKD clinical
trials is aimed at confirming an appropriate blood pressure
target, as well as identifying the proper pharmacologic
agents for blood pressure management (Clinical Trials ID
NCT00283686). Of note, although hypertension is seen in the
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majority of patients with ADPKD, the effect of CD on blood
pressure is described in just 9 of 18 studies reviewed.11,18,19,23–28
This is a reflection of the differing primary end points of the
studies reviewed; we speculate that because pain was the
principal impetus for surgical management in the great ma-
jority of these studies, the foremost goal of the authors was
directed toward defining the role of CD in pain management,
with only some groups investigating additional effects of CD.
The effect of CD on hypertension in patients with ADPKD
is inconsistent among the studies reviewed; however, CD at
the very least does not consistently precipitate worsening
hypertension, and either no change or variable improvement
may be reasonably expected by the majority of patients after
the procedure. Three groups noted that hypertension status
and medication did not change.23,24,28 Elzinga and col-
leagues24 took three blood pressure measurements on suc-
cessive days after CD and averaged them; they reported no
perioperative improvement in hypertension. Elashry and co-
workers23 also reported no change in blood pressure after CD
with a mean follow-up of 7 months. Hemal and colleagues28
reported no change in blood pressure status in either of the
patients after 8 or 10 months of follow-up; both remained on
an antihypertensive drug regimen after the procedure.
Several of the studies reviewed demonstrated mixed re-
sults with regard to blood pressure control. In Dunn and co-
workers’18 experience, after a mean follow-up of 27 months,
hypertension was worse in 5 of 15 patients but was un-
changed or improved in the remaining 10. Lee and associ-
ates26 reported on 21 patients with preoperative hypertension
and noted worsening of blood pressure control in 6 patients
and improvement in 14. They also noted that hypertension
developed in one normotensive patient subsequent to the
procedure. Nevertheless, this study revealed an overall im-
provement in the antihypertensive therapeutic index (ATI)
after a mean follow-up of 32 months, indicating that for some
of the patients, but not for all, LCD was helpful in decreasing
dependence on medical management of hypertension. In our
study of 18 patients over a mean follow-up of 130 months, we
noted that the ATI showed no statistically significant differ-
ence, but there was a trend toward a higher index.11
Others have reported an overall improvement in blood
pressure control after CD. Fleming and Barry19 noted that 6 of
22 patients with preoperative hypertension experienced im-
provement on discharge, while blood pressurewas unchanged
in the remaining 16 patients. Ye27 demonstrated a statistically
significant decline inmean systolic anddiastolic bloodpressure
in his study of 260 patients, although length of follow-up was
not clearly specified in this study. Fryczkowski and cowork-
ers25 pointed out that preoperative hypertension declined in
four of six patients after a mean follow-up of 36 months.
Theoretically, reducing pressure on surrounding paren-
chyma—thereby minimizing ischemia-induced activation of
the RAAS—could potentially decrease blood pressure in
ADPKD patients. Nevertheless, the collective data published
on this topic, while suggesting a potential role for CD in
helping to control hypertension in patients with ADPKD,
does not show this to be consistently reproducible. It should
be noted that comparison among studies is complicated by
varying definitions of ‘‘hypertension control’’ as well as dif-
ferences in follow-up duration; in addition, reports often do
not include a review of the preoperative and postoperative
medications either in number or dose. Furthermore, the per-
vasive absence of an appropriate noninterventional control
arm with which to compare the trajectory of hypertension in
patients with ADPKD undergoing CD also limits the inter-
pretation of these studies.
A prospective study of CD with long-term follow-up and
suitable controls would help provide a more definitive an-
swer regarding the role of CD in contributing to blood pres-
sure control in patients with ADPKD. Alternatively, a
retrospective 1:2 match with hypertensive patients with
ADPKD who demonstrated similar ATI but did not undergo
CD would be helpful in validating these results.
Another caveat in evaluating the effect of CD on blood
pressure is a variable degree of renal hilar dissection that oc-
curred among patients during the procedure. The potential
impact of renal denervation is significant, given the results of
ongoing studies, such as Symplicity’s (Medtronics) catheter-
based renal sympathetic denervation.29
Renal denervation by catheter radiofrequency ablation has
been shown to significantly lower blood pressure in patients
with resistant hypertension.29,30 While inappropriate to con-
clude that mechanical disruption of the RAASwas the driving
force in blood pressure alteration of the patients of this review,
it is not unreasonable to postulate that the hypertension-
lowering effects seen in renal sympathetic denervation may
have contributed to the changes in blood pressure after sur-
gical CD.
Renal function
Renal function is compromised in ADPKD because of pa-
renchymal invasion and compression by dysregulated cyst
formation that concomitantly induces fibrosis and atrophy of
surrounding tissue by recruiting macrophages and fibro-
blasts. Of all patients with ADPKD, at least half will progress
to ESRD by age 60.31 Contributing factors to ESRD progres-
sion include poorly managed hypertension and early onset of
disease.1 Therefore, it is critical to determine the impact of CD,
if any, on the natural progression to ESRD in this subset of
patients. Given the controversy on the subject, it is not sur-
prising that the data are variable regarding postoperative
impact on renal function. Of the studies reviewed, postoper-
ative renal function was assessed in 13 and not mentioned in
the remaining 5 studies.10–12,16,18,19,23–28,32
The study by Bricker and Patton10 published in the New
England Journal of Medicine in 1957 reported that surgical de-
cortication of the kidney ‘‘further compromises its functional
ability.’’ This conclusion was based on a comparison of the
preoperative and postoperative creatinine clearance (CrCl) of
two CD patients with those of two nonsurgical controls after
13 months of follow-up. The next publication—by Milam and
associates13 in 1963—stated that CD did not improve renal
function in their two patients, asmeasured by inulin and para-
aminohippuric acid clearance. They postulated, however, that
renal function before surgery may well be an important factor
in determining postoperative function.
Later studies by six groups demonstrated that CrCl, used to
measure renal function, was unchanged after CD. Flemming
and Barry19 evaluated 28 patients, 14 of whom had abnormal
preoperative CrCl values. They reported that serum creatinine
levels initially increased in 20 patients immediately after sur-
gery but subsequently regressed to baseline by the time of
discharge. Length of follow-up was not specified in this study.
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Teichman andHulbert12 noted that therewas no change in any
of their six patients when they compared preoperative and
postoperative serum creatinine levels, with follow-up varying
from 6 to 40 months. Brown and coworkers32 followed their
patients for 12 to 28months and reported that serum creatinine
levels, which were measured in three of eight patients, were
unchanged. Elashry and colleagues23 found that in two
ADPKD patients with functioning kidneys, preoperative and
postoperative CrCl levels were unchanged at 7 months of
follow-up. Similarly, Elzinga and coworkers,24 after a mean
follow-up of 21months, observed no change inCrCl in patients
with ADPKD who had normal preoperative renal function.
Ye’s27 study of 260 patients also showed no statistically sig-
nificant change in preoperative vs postoperative CrCl values.
In addition, in four reports, there are mixed results with
regard to post-CD renal functional outcomes. Hemal and as-
sociates28 observed that in one patient, postoperative CrCl
transiently decreased, then returned to preoperative levels; in
the other patient, CrCl increased by 50% after the procedure.
Dunn and coworkers18 noted that in their study of 16 patients,
15 of whom had normal renal function initially, renal function
declined in one, improved in one, and remained steady in the
remaining patients after surgery; mean follow-up was 27
months. Lee and colleagues26 published a study of 29 patients
with a 32-month mean follow-up. They noted that in all five
patients with a preoperative CrCl < 30mL/min, each expe-
rienced a decline in CrCl postoperatively. One patient of 21
with normal preoperative renal function had a 22% drop in
CrCl at 24months postoperatively, and another patient’s CrCl
levels increased by 49% after 48 months. The remaining 19
patients had stable renal function after surgery.
Our study showed that mean estimated glomerular filtra-
tion rate (GFR) decreased significantly postoperatively from
preoperative levels at last patient contact. The mean preop-
erative CrCl level of patients in whom ESRD subsequently
developed, however, was 43.4mL/min vs 75.4mL/min for
those inwhomESRDdid not develop (P = 0.01). The decline in
mean CrCl of these groups (80% vs 24%, respectively) sug-
gests an association between lower preoperative CrCl and
increased vulnerability to renal functional decline.11
On the other hand, a study by Fryczkowski and cowork-
ers25 reported improved renal function after CD. According to
this report, patient GFR improved by approximately 10% in a
cohort of 15 patients with a mean follow-up of 36 months.
The clinically relevant observation that can be drawn either
by direct report or through extrapolation of the data pub-
lished is that renal function appears to suffer the greatest
impairment after surgery if there is poor baseline renal func-
tion before surgery.10,11,13,18,24,26 Whether LCD itself alters the
natural course of progression to ESRD in patients with com-
promised preoperative renal function remains an open ques-
tion. Elzinga and colleagues24 attempted to answer this
question by comparing the slope of reciprocal serum creati-
nine plots preoperatively and at postoperative follow-up in
patients with renal insufficiency (serum creatinine > 1.4mg/
dL). Because they observed no difference in the rate of renal
deterioration, they concluded that the progression of renal
disease in this subset of patients cannot be attributed to the
CD procedure. In our experience, we observed that a decline
of renal function appeared to be more pronounced postop-
eratively if there was initial marked compromised function,
which was defined as a CrCl of less than 30mL/min.11
The analysis is again limited by the potential effect of renal
denervation on renal function by aggressive hilar dissection,
as the Symplicity study suggests that denervationmay impact
renal function. The mechanism posited by the authors is a
protective one via blockade of adenosine A1 receptors and
subsequent maintenance of renal blood flow and glomerular
filtration.29 It is possible that this may have impacted renal
function of patients in varying degrees, depending on the
individual surgery.
A further limitation of all the studies reviewed is the ab-
sence of an appropriately matched control arm of patients
with ADPKD who did not undergo surgical intervention.
Either a retrospective 1:2 match with ADPKD patients of
similarly staged renal function who did not undergo CD or a
prospective study of surgical CD with a large sample size,
long-term follow-up, and adequate controls is needed to
elucidate the role of this procedure in altering the natural
progression to ESRD in patients with ADPKD. Until such
insight is gained, we advocate caution in performing LCD in
patients with an initial CrCl of < 30mL/min, because several
studies suggest that those patients may be at a higher risk for
subsequent renal deterioration.
Pain control
Perhaps the most pivotal role that surgical CD has to play
for patients with ADPKD lies in its effect on pain. Chronic
pain is a common complaint in this patient population, with a
negative impact on sleep, activity, mental status, and social
relationships.33While pain is one of themost common reasons
that people seek medical intervention in general, it is one of
the most difficult symptoms to treat, and there is no existing
standardized protocol for its management in patients with
ADPKD.34 The incidence of pain in these patients is difficult to
assess, but according to one study, 60% of patients are af-
flicted with pain related to their disease.35 Certainly, treat-
ment of pain should be at the forefront of the physician’s goals
in caring for this patient subset.
Currentmethodology in pain therapy includes noninvasive
treatments such as ice, heat, whirlpool, massage, and postural
training. Analgesics, progressing from nonsteroidal inflam-
matory drugs to narcotics, and transcutaneous electrical nerve
stimulation are additional options to be explored.34 While
surgery is clearly indicated in the presence of malignant cysts,
another potential indication is for reduction of chronic pain in
patients with ADPKD in whom conservative measures of
pain control have failed. According to the literature, the role of
surgical intervention in relieving ADPKD-related pain is un-
ambiguous.
Among the reports we reviewed, pain was an indication for
decortication surgery in 15 studies, while the remaining 3 did
not address the impact of this procedure on pain. On data
review, it is clear that CD has an unmistakable utility in al-
leviating chronic pain in patients with ADPKD. Indeed, all the
studies that evaluate this end point unanimously demonstrate
a significant improvement in pain after surgery, which ap-
pears to be durable over several years.
The first report of cyst decortication by Rovsing8 docu-
ments postoperative pain relief in his three patients. Elashry
and coworkers23 used a visual pain analog scale in a study of
two patients over 7 months and reported a mean 90% reso-
lution in pain. Hemal and associates28 reported pain relief,
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defined as ‘‘prompt and sustained improvement of symp-
toms’’ in their study of two patients with 8 to 12month follow-
up. McNally and colleagues36 reported a decline in pain from
a mean 7.4/10 to 2.3/10 in their study of seven patients
spanning 14 months. Chehval and Neilsen37 described pain
relief in all three of their patients at a mean follow-up of 16
months.
Brown and coworkers32 used subjective feedback via in-
terview and documented 40% pain relief in one patient, 50%
pain relief in another, and 90% to 100% pain relief in four
patients, with follow-up of eight patients ranging from 12 to
28 months. Teichman and Hulbert12 evaluated six patients,
five of whom experienced resolution of pain after a follow-up
ranging from 6 to 40 months. Elzinga and associates24 found
that the probability of remaining pain free at 1-year follow-up
after CD was 80%; after 2 years, it was 62%. Fryczkowski and
colleagues25 used a visual pain analog scale and noted that
73% of his 15 patients were pain-free at 24 months. Dunn and
coworkers18 also used a visual pain analog scale to demon-
strate a mean 62% pain improvement in 11/15 patients at a
mean follow-up of 27 months.
Lifson and colleagues38 described five of seven patients as
pain free at the conclusion of follow-up,which lasted from 3 to
63 months. In their study of 29 patients, Lee and associates26
reported > 50% pain improvement in 81% of patients at a
mean follow-up of 32 months. Ye,27 who averaged 60 months
of follow-up in a study of 260 patients, revealed that 1-year
postoperative pain relief was achieved in 92% of cases, while
5-year pain relief was sustained in 81% of cases.
Our group reported on 18 patients with a mean follow-up
of 130 months. Of patients last contacted, 67% reported > 50%
improvement in pain and would readily undergo the proce-
dure again.11
Of note, different methods of pain assessment were used by
different groups. These included subjective patient reports,
the use of pain analog scales, and others. Duration of follow-
up also varied substantially among the studies evaluated. Yet
despite variability in methodology and follow-up, there is a
demonstrable trend that surgical intervention has a positive,
reproducible, and durable impact in reducing pain for the
majority of patients with ADPKD. Based on these studies, a
strong case can be made for the clinical application of CD in
treating disease-related pain in this patient population.
Conclusion
The studies reviewed do not have identical end points or
consistent methods for assessing hypertension control, renal
functional outcomes, or pain relief. Nevertheless, the review
of the literature we provide may help elucidate the effect of
CD on these parameters and guide clinical decision making
regarding potential candidates for this procedure.
CD has not been definitively and consistently shown to
lower blood pressure in patients with ADPKD. Of the studies
examined that included this end point, hypertension after
surgery was unchanged in three, was variable in three, and
was improved in three. Pharmacotherapy is still the mainstay
in managing blood pressure, and trials currently under way
are expected to offer insight into the optimal hypertensive
control. The putative role of CD in blood pressure control
continues to be defined in these patients, especially in light of
forthcoming research on renal nerve interruption.
While we cautiously conclude that renal function does not
improve after the surgery, the impact of CD on the trajectory
of renal failure in patients with ADPKD with normal renal
function appears to be nil. Of 13 studies that examine this
outcome, two suggested worsening renal function, four
demonstrated mixed results with function declining in some
patients and improving in others; six studies showed no
change, and one showed improved function. Some studies
reviewed, including our own, demonstrate an association
between compromised baseline renal function and acceler-
ated postoperative decline. Despite an exhaustive review of
the literature, however, we are unable to find any studies
within the last 30 years that used the appropriate patient
controls necessary for drawing definitive clinical conclusions
regarding the postoperative deterioration of renal function
noted in the subset of ADPKD patients with renal insuffi-
ciency (CrCl < 30mL/min). This remains a potential area for
additional research.
The literature demonstrates that pain is a frequent indica-
tion for surgical intervention and that chronic pain associated
with ADPKD is an important factor in quality of life for these
patients. We examined 18 studies of which 15 cited pain
control as a primary end point. All 15 studies demonstrated
that surgical CD was instrumental in relieving pain. A con-
sistent theme among the studies reviewed is that CD is ef-
fective in the treatment of disease-related chronic pain for the
majority of patients with ADPKD and is durable in the ma-
jority of patients out to at least 5 years.
When evaluating the major symptoms of ADPKD—
hypertension, renal function, and pain control—it is clear that
surgical intervention should be considered predominantly
among patients in whom conservative measures of pain relief
have failed and who have stage 2 or higher levels of renal
function (ie, Cr Cl > 45mL/min). These patients can reason-
ably expect to experience durable relief of their painful
symptoms without detriment to renal function.
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Abbreviations Used
ADPKD¼ autosomal dominant polycystic kidney
disease
ATI¼ antihypertensive therapeutic index
CD¼ cyst decortication
CrCl¼ creatinine clearance
CT¼ computed tomography
ESRD¼ end-stage renal disease
GFR¼ glomerular filtration rate
LCD¼ laparoscopic cyst decortication
MRI¼magnetic resonance imaging
RAAS¼ renin-angiotensin-aldosterone system
RCC¼ renal-cell carcinoma
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